Business
Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido®
ZTlido® profile has been viewed as a leading prescription lidocaine patch by pain specialists. Based on the independent market research conducted by Syneos
About this update from Scilex Holding Company
[{"type":"text","content":"ZTlido® profile has been viewed as a leading prescription lidocaine patch by pain specialists. Based on the independent market research conducted by Syneos Health Consulting (“Syneos”), with the new campaign, health care providers (HCPs) report increased awareness and substantial intent in utilization for ZTlido® with peak sales potential projected to be over $500 million in the next 6 years.1Market research with HCP’s treating PHN pain demonstrated future expanded utilization following increased awareness to ZTlido® Product Profile.Neurologists and HCPs estimate that they will prescribe ZTlido® to 64% of their patients in cases where they are using market leading neuropathic pain products. 1Unlike conventional lidocaine patches, ZTlido® utilizes ZTech technology—an advanced adhesion and delivery system designed for a lidocaine patch, allowing it to efficiently deliver 12 hours of pain relief for patients.Vast majority of the respondents’ growth in the use of ZTlido® will occur in the first 3-year time period, suggesting that the current promotion efforts will generate near-term growth in ZTlido® use.ZTlido® new prescriptions (NRxs) grew by 34% and total prescriptions (TRxs) grew by 27% in YTD Q2-2023, compared to Q2-2022. NRxs grew by 38% and TRxs grew by 31% in YTD Q2-2023, compared to YTD 2022.Scilex projected 105,900 total prescriptions in Q2-2023, which is the highest quarter to date, and ZTlido® has grown by high double digits for the past 4 quarters, compared to the corresponding period in previous years.ZTlido® covered lives on insurance plans have increased by over 35MM in Q2-2023, compared to Q2-2022. PALO ALTO, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the results from a primary market research study with 80 pain specialists conducted on behalf of the Company by Syneos. The study was a primary market research analysis in which 80 US-based pain specialists and HCPs were presented with various product attributes, including efficacy, safety and tolerability, to determine comparative prescribing prefer...